Alok Khorana: Six Years of Growth and Transformation at National Blood Clot Alliance
Alok Khorana, Vice Chair of the Taussig Cancer Institute at Cleveland Clinic, shared a post on LinkedIn:
“It’s been a dynamic six years of growth and transformation as I reach the end of my second and final term as Chair of the Medical and Scientific Advisory Board of National Blood Clot Alliance. From creating the Council for Emerging Researchers in Thrombosis (CERT) to effective public policy advances at state and federal levels such as the passage of the Emily Adkins Act in Florida, I couldn’t have asked for a better partner than Leslie Lake. She is an inspirational leader who has changed the boundaries of what’s possible in this patient-led organization.
I’m excited to hand off leadership to incoming Chair Jeffrey Zwicker who I’m absolutely confident will lead the Board to newer and greater heights.
Finally, I’m absolutely delighted to remain involved with MASAB and NBCA as Chair Emeritus. Much has been done to alleviate the public health and individual burden of thromboembolism but much remains to be done.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 23:18Claire Hills: New Paper on Immune Surveillance and Immune Evasion of Senescent Cells
-
Aug 14, 2026, 23:16Are We Overlooking What Matters Most to Women with Von Willebrand Disease? – RPTH Journal
-
Aug 14, 2026, 23:15Markus Müller: A New Base Editing Approach Targeting PCSK9 to Lower Cholesterol Levels
-
Aug 14, 2026, 23:14Chokri Ben Lamine: Avatrombopag in Hematology – Dosing and Monitoring
-
Aug 14, 2026, 23:13Bianca Rocca: PRECISE-DAPT Score Identifies Bleeding Risk After CABG in Patients With POAF
-
Aug 14, 2026, 19:04Ravi Kumar: Why Lupus Anticoagulant Predicts Clots, Not Bleeding
-
Aug 14, 2026, 18:53Veli Bakalov: The Number Every Hematologist Should Know in Polycythemia Vera
-
Aug 14, 2026, 18:41Marta Velia Antonini: Can Nitric Oxide Protect the ECMO Circuit Without Systemic Anticoagulation?
-
Aug 14, 2026, 18:30Irina Gontschar: What the Epkinly FDA Review Teaches Us About Sponsor Oversight